CEPI to in­vest up to $80M on ChA­dOx vac­cine plat­form, pre­vi­ous­ly used in As­traZeneca/Ox­ford Covid jab

The Coali­tion for Epi­dem­ic Pre­pared­ness In­no­va­tions (CEPI) is al­lo­cat­ing up to $80 mil­lion for the Uni­ver­si­ty of Ox­ford to de­vel­op vac­cine pro­to­types, in­clud­ing ones based on its ChA­dOx ade­n­ovirus vec­tor plat­form, to com­bat dis­eases with out­break po­ten­tial. ChA­dOx is the same plat­form used by the uni­ver­si­ty and As­traZeneca to de­vel­op their Covid vac­cine Vaxzevria.

Pro­to­type ChA­dOx vac­cines will tar­get a range of high-risk vi­ral fam­i­lies, de­signed to be mod­i­fied if a new “Dis­ease X” is de­tect­ed that can lead to an out­break. The vac­cines will ad­vance through pre­clin­i­cal and ear­ly clin­i­cal test­ing, and will be­come a part of the knowl­edge and da­ta re­source Glob­al Vac­cine Li­brary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER